The federal jury in a patent trial has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing on patents for hepatitis C drugs.

The award is far below the damages Merck sought, but the trial moves to a new phase Wednesday. The jury, in San Jose, California, then will decide whether Merck & Co. is due royalties on sales of Gilead’s hepatitis C drugs, Harvoni and Sovaldi.